MedTrace Logo

Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer

NCT00751790 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2014-07-25

Study results available
· View outcomes & findings →

Summary

Efficacy and safety of a triptorelin 6-month formulation in patients with advanced prostate cancer. It was assumed that during the study treatment \>90% of the patients would achieve and maintain castrate levels of serum testosterone.

Conditions

  • Prostatic Neoplasm

Interventions

DRUG

triptorelin embonate (INN)

Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks

Sponsors & Collaborators

  • Debiopharm International SA

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • South Africa

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00751790 on ClinicalTrials.gov